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Pancreatitis is an inflammatory disease of the pancreas that was first identified in the 1600s.  
Symptoms for pancreatitis include intense abdominal pain, nausea, and malnutrition.  Hereditary 
pancreatitis (HP) is a genetic condition in which recurrent acute attacks can progress to chronic 
pancreatitis, typically beginning in adolescence.  Mutations in the PRSS1 gene cause autosomal 
dominant HP.  The 1996 discovery of a PRSS1 mutation causative for hereditary pancreatitis was 
in direct contrast to much of the medical community’s long-held beliefs that pancreatitis is 
primarily caused by alcoholism and gallstones.  HP strongly impacts quality of life and is a risk 
factor for pancreatic cancer, making it a public health concern.  Our understanding of HP is still 
limited, and chronic pancreatitis remains a serious disease for which significant treatment options 
are lacking.  Questions remain regarding the exact mechanism of cancer development and risk 
factors in families with HP.  Furthermore, HP has unpredictable duration, severity, complications, 
and outcomes.  It is often accompanied by systemic diseases and complications, such as diabetes 
mellitus.  Therefore, research is needed to further define the natural history of HP, its psychosocial 
implications, and its interactions with other risk factors. The overall goal of this research is to 
improve quality of life, patient care, and treatment options for individuals with this debilitating 
disease by understanding more about the natural history of the condition and collecting information 
on attitudes, concerns, and perspectives.  The Hereditary Pancreatitis Study at the University of 
Pittsburgh has collected genetic, medical, and environmental data from hundreds of American 
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families with pancreatitis since the mid-1990s.  I have described the natural history of HP in this 
American cohort, analyzed risks for pancreatic cancer and diabetes based on family history, and 
assessed large HP pedigrees with pancreatic cancer.  My analysis indicates that this American 
cohort is similar to published studies on the French, Danish, and other European populations.  I 
also created a follow-up questionnaire for these participants to gather information on attitudes, 
risks for pancreatic cancer, and views on a pancreatic center of excellence and its services.  Data 
from this questionnaire will be relevant to improving patient care in future studies. 
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1.0  INTRODUCTION 
1.1 BACKGROUND 
1.1.1 Basic Pancreas Physiology 
The pancreas is a gland organ that is a part of the human digestive system.  It is located in the 
abdominal cavity in a position both posterior and inferior to the stomach.  Within the pancreas is 
the pancreatic duct, which joins the common bile duct to empty into the duodenum.  The pancreas 
can further be divided into the exocrine pancreas and the endocrine pancreas (Das et al., 2014). 
 
The majority of pancreatic cells are exocrine cells, comprising over 95% of its mass (Das et al., 
2014).  The purpose of the exocrine pancreas is to secrete precursor digestive enzymes to digest 
the carbohydrates, proteins, and lipids found in the chyme.  The exocrine pancreas is composed of 
acini, or clusters of acinar cells that surround a saclike cavity, or acinar lumen (Pandiri, 2014).  
Acinar cells secrete zymogens into this lumen, which travel through intralobular ducts into the 
main pancreatic duct.  The zymogens secreted by acinar cells include trypsinogen, 
chymotrypsinogen, pancreatic lipase, and amylase (Pandiri, 2014).  Ductal cells secrete 
bicarbonate through the CFTR membrane protein, which flushes zymogens through the ducts and 
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into the duodenum (Choi et al., 2001; Pandiri, 2014).  Once in the duodenum, bicarbonate 
neutralizes the acidic chyme and the zymogens are activated. 
 
The endocrine pancreas secretes hormones directly into the blood vessels to regulate blood glucose 
levels.  It is composed of cells called the islets of Langerhans, which are classified into four major 
types according to their secretions.  Alpha cells secrete glucagon, and beta cells secrete insulin, 
which increase and decrease blood glucose levels, respectively.  Somatostatin is secreted by delta 
cells, and pancreatic polypeptide by gamma cells.  The endocrine and exocrine functions of the 
pancreas make it a vital organ for digestion and blood glucose regulation. 
1.1.2 Pancreatitis Overview 
1.1.2.1 Classification 
Pancreatitis is the inflammation of the pancreas, for which major symptoms include intense 
abdominal pain, nausea, and vomiting.  There are multiple forms of pancreatitis that are defined 
according to the frequency, severity, and length of a pancreatic attack.  These major categories of 
pancreatitis are acute pancreatitis (AP), recurrent acute pancreatitis (RAP), and chronic 
pancreatitis (CP). 
 
Acute pancreatitis is defined as a sudden inflammation of the pancreas, which is believed to have 
been first described by the Dutch anatomist Nicholaes Tulp in 1652 (Pannala, Kidd, & Modlin, 
2009; Tulp, 1652).  It is diagnosed in the presence of two out of three of the following features: a 
pattern of abdominal pain consistent with the disease, serum lipase or amylase activity that is 
increased by a factor of three, and specific findings on contrast enhanced computed tomography 
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(CECT), magnetic resonance imaging (MRI) or transabdominal ultrasonography (Banks et al., 
2013; Working Group, 2013).  It can be further sub classified according to severity into mild AP, 
moderately severe AP, and severe AP (Banks et al., 2013; Petrov & Windsor, 2010; Vege et al., 
2009).  Individuals who have had one or more acute pancreatic attacks are at risk to develop 
recurrent acute pancreatitis and chronic pancreatitis, particularly in the presence of alcohol and 
tobacco exposure (Yadav, O'Connell, & Papachristou, 2012). 
 
Recurrent acute pancreatitis refers to the occurrence of more than one acute pancreatic attack in 
an individual (Chari & Singer, 1994; Sarles et al., 1965).  Some classifications, particularly the 
revised Marseille and Marseille-Rome classifications have removed the term RAP due to the 
difficulty of distinguishing it from chronic pancreatitis (Sarles et al., 1989; Singer, Gyr, & Sarles, 
1985; Testoni, 2014).  
 
Chronic pancreatitis is a progressive disease involving inflammation of the pancreas.  It results in 
permanent morphologic changes to the pancreas (fibrosis), typically resulting in both endocrine 
and exocrine insufficiency (Lankisch, Lohr-Happe, Otto, & Creutzfeldt, 1993; Steer, Waxman, & 
Freedman, 1995).  Symptoms of CP include frequent or persistent abdominal pain, nausea, diarrhea 
and bloating.  Loss of pancreatic function leads to an impairment in the production of digestive 
enzymes, which leads to steatorrhea (presence of excess fat in stool), weight loss, and malnutrition 
if not treated.  These diseases are interrelated, and individuals with AP and RAP have an increased 
risk for CP, especially in the presence of environmental and/or genetic risk factors (Mounzer & 
Whitcomb, 2013; Nojgaard et al., 2011). 
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Pancreatitis can also be classified as idiopathic sporadic, familial, or hereditary based on an 
individual’s family history and/or mutation status.  Idiopathic sporadic pancreatitis is defined as 
pancreatitis in an individual without a family history or a known etiology.  Familial pancreatitis is 
the occurrence of pancreatitis in a family that is greater than expected by chance alone.  Hereditary 
pancreatitis (HP) is a sub-type of familial pancreatitis.  HP is diagnosed by meeting one of 
two criteria: (1) pancreatitis in two or more related individuals in two or more generations of a 
family; (2) an identified pathogenic germline mutation (Whitcomb DC, 2010). 
1.1.2.2 Risk Factors 
Historically, the primary causes of pancreatitis were believed to be gallstones for acute pancreatitis 
and alcoholism for chronic pancreatitis.  While this is not always the case, they remain major 
contributors to this disease.  About 30% of AP cases in the United States are caused by alcoholism 
(Yang, Vadhavkar, Singh, & Omary, 2008).  Gallstones are another major cause of AP, being 
responsible for 35 – 40% of cases worldwide (Forsmark, Baillie, Practice, Economics, & Board, 
2007).  Additional known causes for pancreatitis include other obstructions, smoking, 
hypercalcemia, hypertriglyceridemia, drugs, infections, toxins, complications from endoscopic 
retrograde cholangiopancreatography (ERCP), autoimmune disease, genetic mutations, and 
trauma (Yadav & Lowenfels, 2013). 
1.1.3 Hereditary Pancreatitis 
1.1.3.1 Description and Clinical Course 
Hereditary pancreatitis is a genetic condition characterized by an onset of acute pancreatitis, 
typically in childhood.  This acute pancreatitis then progresses to recurrent acute pancreatitis, with 
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the development chronic pancreatitis usually by early adulthood.  Clinical course and symptoms 
are variable among patients, and the average age of symptom onset is twelve years (Howes et al., 
2004). 
1.1.3.2 Symptoms and complications 
The symptoms and complications of hereditary pancreatitis are similar to those seen in patients 
with chronic pancreatitis of non-genetic etiology.  Pain is a common symptom, but difficult to 
treat, and quality of life is significantly impacted by pain in individuals with HP that develop 
chronic pancreatitis (Mullady et al., 2011).  Constant pain, independent of severity, in patients with 
CP is associated with increased rates of disability, use of analgesics, and hospitalizations (Mullady 
et al., 2011). 
 
Damage to the pancreas from chronic pancreatitis typically results in exocrine insufficiency, or the 
inability of the pancreas to release sufficient amounts of digestive enzymes.  The primary symptom 
of exocrine insufficiency is fat malabsorption, resulting in steatorrhea, or excess fat and oil in the 
stool (Pezzilli, 2009).  Other symptoms of maldigestion include weight loss, gastrointestinal 
distress (e.g. gas, pain, and diarrhea), and nutritional deficiency of fat-soluble vitamins (A, D, E, 
K) (Pezzilli, 2009).  The cumulative risk for pancreatic exocrine insufficiency in association with 
hereditary pancreatitis at 50 years of age is estimated to be 37.2% (Howes et al., 2004). 
 
Diabetes mellitus is frequently seen in association with hereditary pancreatitis (Howes et al., 2004; 
Rebours, Boutron-Ruault, Schnee, et al., 2009).  A distinct type of diabetes mellitus, type 3c, arises 
from loss of pancreatic tissue from CP, surgery, or other diseases (American Diabetes, 2011).  
Type 3c differs from type 1 diabetes because there is loss of both insulin (beta cells) and glucagon 
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(alpha cells), creating a risk for hypoglycemia and pancreatic cancer (Cui & Andersen, 2011).  The 
cumulative risk for diabetes at 50 years of age in patients with hereditary pancreatitis is close to 
50% (Howes et al., 2004).  
 
It is well known that inflammation is a risk factor for cancer (Weiss, 2014).  A study on the French 
population found that HP is associated with an increased risk of pancreatic adenocarcinoma 
(standardized incidence ratio = 87) (Rebours et al., 2008).  In contrast, patients with alcoholic CP 
have 16 – 27 times the relative risk of pancreatic adenocarcinoma compared to the general 
population (Lowenfels et al., 1993; Malka et al., 2002; Rebours et al., 2008).  Pancreatic cancer is 
an aggressive and difficult to treat cancer with a 6.7% five-year survival rate (Howlader N, 2014). 
 
Lifespan does not appear to be reduced in individuals with hereditary pancreatitis who do not 
develop pancreatic cancer (Rebours, Boutron-Ruault, Jooste, et al., 2009).  However, quality of 
life is significantly reduced by the disease and its associated symptoms beginning at an early age. 
1.1.3.3 Molecular Genetics – PRSS1- related Hereditary Pancreatitis 
Comfort and Steinburg (1952) were the first to report a pedigree of a family with hereditary 
pancreatitis (Comfort & Steinberg, 1952).  However, it wasn’t until 1996 that a gene for hereditary 
pancreatitis was mapped to chromosome 7q (Le Bodic et al., 1996; Whitcomb, Preston, et al., 
1996).  In the same year, Whitcomb et al. (1996) identified a missense mutation in the cationic 
trypsinogen gene (PRSS1) in a large family (Whitcomb, Gorry, et al., 1996).  Since this discovery, 
we know that hereditary pancreatitis is most often caused by gain of function mutations in the 
PRSS1 gene. 
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PRSS1-related hereditary pancreatitis is an autosomal dominant condition.  The PRSS1 gene 
encodes trypsinogen, which is the zymogen for trypsin-1, a serine protease.  Trypsinogen is 
secreted by acinar cells in the exocrine pancreas and washed through the pancreatic duct into the 
small intestine (Pandiri, 2014).  Once in the duodenum, trypsinogen is activated by enterokinase 
into its active form – trypsin-1.  Trypsin-1 is a major digestive enzyme and activates other 
pancreatic zymogens in the small intestine.  
 
Pathogenic PRSS1 mutations can be divided into two types – mutations that result in a form of 
trypsinogen that is prematurely activated in the pancreas and mutations that prevent trypsin 
degradation (Gorry et al., 1997; Mounzer & Whitcomb, 2013).  Still, both types of mutations result 
in elevated trypsin levels within the pancreas.  Trypsin activity leads to damage of the pancreatic 
tissue, as well as inflammation by triggering an immune system response (Singhi et al., 2014).  
Histologic findings include pancreatic atrophy, fibrosis, and replacement of peripheral tissue with 
adipose (Pandiri, 2014).  Of individuals with a mutation in PRSS1, about 90% have the mutation 
R122H or N29I (Howes et al., 2004; Rebours, Boutron-Ruault, Schnee, et al., 2009).  Less 
commonly seen mutations include A16V, R122C, N29T, D22G, and K23R (Howes et al., 2004).  
About 65 – 100% of families with hereditary pancreatitis have a mutation in the PRSS1 gene, and 
PRSS1-related pancreatitis is estimated to have a penetrance of about 80% (Howes et al., 2004).  
Copy number variations of the PRSS1-PRSS2 (anionic trypsinogen) locus have also been 
associated with chronic pancreatitis (J. M. Chen, Masson, Le Marechal, & Ferec, 2008).  
1.1.3.4 Molecular Genetics – Other Genes 
There are a number of genes in addition to PRSS1 in which pathogenic variants have been linked 
to pancreatitis, particularly SPINK1, CFTR, and CTRC (J. M. Chen & Ferec, 2009, 2012; 
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Rosendahl et al., 2013; Whitcomb, 2013).  Additional risk genes include CASR, UBR1 (Zenker et 
al., 2005), SBDS (Boocock et al., 2003), CEL (Raeder et al., 2006), CTSB, CLDN2, CPA1, GGT1, 
MMP1, and MTHFR (Shelton & Whitcomb, 2014).  Disease mechanisms for many of these genes 
are complex, and gene-gene and gene-environment interactions are not fully defined (LaRusch, 
Barmada, Solomon, & Whitcomb, 2012). 
 
The SPINK1 gene encodes serine protease inhibitor, Kazel-type 1.  In the pancreas, SPINK1 
functions as an important inhibitor of trypsin, inhibiting as much as 20% of trypsin activity to 
defend the pancreas (Laskowski & Kato, 1980; Rinderknecht, 1986).  Loss-of-function mutations 
in the SPINK1 gene were found to be associated with chronic pancreatitis in 2000 and are found 
in about 2% of the population (Pfutzer et al., 2000; Witt et al., 2000).  Biallelic loss-of-function 
mutations in SPINK1 may lead to autosomal recessive pancreatitis.  Pathogenic variants in SPINK1 
can act as disease modifiers for individuals with pancreatitis, and compound heterozygosity for 
pathogenic variants in SPINK1/PRSS1 and SPINK1/CFTR in patients with pancreatitis have been 
identified (Rosendahl et al., 2013). 
 
CFTR encodes the cystic fibrosis transmembrane conductance protein, an anionic channel that 
conducts chloride ions in the lungs and intestines, and bicarbonate in the pancreas (Schneider et 
al., 2011).  Cystic fibrosis can be separated into two distinct diseases depending on whether 
chloride conductance is impaired or preserved.  The traditional form of cystic fibrosis is caused by 
severe biallelic CFTR (CFTRSEV) mutations, which impair both bicarbonate and chloride 
conductance through the CFTR channel (Rosendahl et al., 2013).  This traditional form of cystic 
fibrosis is characterized by thick mucus leading to respiratory system damage and susceptibility to 
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infection.  Other major symptoms include pancreatic dysfunction, male infertility, and intestinal 
damage.  The second form of cystic fibrosis is caused by mutations in CFTR that prevent its 
transformation into a bicarbonate-specific channel (CFTRBD) (LaRusch et al., 2014).  CFTRBD 
mutations lead to an inability to fully flush zymogens out of the pancreatic ducts and into the 
common bile duct.  These zymogens remain in the pancreas and can become active, damaging the 
pancreatic tissue.  Sufficient digestion of the pancreas leads to pancreatic attacks.   
 
The CTRC gene encodes the Ca2+-dependent serine protease chymotrypsinogen C.  Chymotrypsin 
C acts as the primary regulator of trypsin.  In the Ca2+-rich environment of the duodenum, 
chymotrypsin C participates in the activation of trypsinogen (Szmola & Sahin-Toth, 2007).  
However, in the pancreas and lower intestines, chymotrypsin C degrades trypsin, defending against 
pancreatitis (Szmola & Sahin-Toth, 2007).  Variants in CTRC that impair the function and/or 
secretion of chymotrypsinogen C have been associated with pancreatitis (Masson, Chen, Scotet, 
Le Marechal, & Ferec, 2008; Rosendahl et al., 2008).  The c.180T>G variant in CTRC is common 
and significantly increases the risk of progression from RAP to CP, particularly in the presence of 
other risk factors such as alcohol and smoking (LaRusch et al., 2015; Masson et al., 2008).  
 
More information is available on pancreatitis genetics in the article “Shelton CA, Whitcomb DC. 
Genetics and treatment options for recurrent acute and chronic pancreatitis. Curr Treat Options 
Gastroenterol. 2014;12(3):359-71” found in Appendix C.  
1.1.3.5 Population Data 
Hereditary pancreatitis is considered a rare genetic condition.  Population-based studies have been 
performed in France, Denmark, and across 14 European countries (Howes et al., 2004; Joergensen, 
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Brusgaard, Cruger, Gerdes, & Schaffalitzky de Muckadell, 2010; Rebours, Boutron-Ruault, 
Schnee, et al., 2009).  A study on the French population estimates a prevalence for PRSS1-related 
hereditary pancreatitis of at least 0.3/100,000 (Rebours, Boutron-Ruault, Schnee, et al., 2009).  
This study also found PRSS1 gene mutations in about 2/3 of individuals with hereditary 
pancreatitis, with a penetrance of 93% (Rebours, Boutron-Ruault, Schnee, et al., 2009).  A similar 
penetrance (96% at 50 years of age) was identified in a registry representing 14 European countries 
(Howes et al., 2004).  In the Danish population, about 1% of all patients with pancreatitis have 
been identified to have hereditary pancreatitis (Joergensen et al., 2010).  Studies on the prevalence 
of HP in the Japanese population are similar to the prevalence seen in Western countries. 
1.1.3.6 Genetic Counseling and Testing 
The indications to offer genetic testing of PRSS1 in a symptomatic patient are (1) unexplained 
RAP; (2) unexplained CP; (3) family history of pancreatitis in a first or second-degree relative; 
and/or (4) unexplained episode of pancreatitis in a child requiring hospitalization (Ellis, Lerch, 
Whitcomb, & Consensus Committees of the European Registry of Hereditary Pancreatic Diseases, 
2001).  Predictive molecular genetic testing is recommended for only patients over 16 years of age 
with a first-degree relative with an identified HP-related mutation (Ellis et al., 2001). 
 
Testing should begin with a targeted mutation analysis of exons 2 and 3 or complete sequence 
analysis of the PRSS1 coding regions.  Deletion/duplication analysis can be considered if a 
mutation is not identified.  Genes offered on commercial chronic pancreatitis next-generation and 
Sanger sequencing panels include CASR, CFTR, CPA1, CTRC, PRSS1, and SPINK1.  Prenatal 
testing is also available but may be controversial given that this disease is not 100% penetrant. 
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Assessment of a family medical history should include at least a three-generation pedigree, 
including family history of pancreatitis, age of onset, ages of diagnosis for multiple pancreatic 
attacks, and pancreatic cancer (Solomon & Whitcomb, 2012).  Other valuable family history 
information includes smoking, alcohol use, diabetes, exocrine insufficiency, male infertility, cystic 
fibrosis, chronic sinusitis, and nasal polyps (Solomon & Whitcomb, 2012).  Recurrence risk is 
dependent on genotype and exposure environmental risk factors (Solomon & Whitcomb, 2012).  
 
A 2001 study on motivations and concerns with regard to genetic testing for hereditary pancreatitis 
found that the largest concern for genetic testing was insurance discrimination (Applebaum-
Shapiro, Peters, O'Connell, Aston, & Whitcomb, 2001).  Furthermore, the major motivation to 
participate in research for hereditary pancreatitis was to help current family members and future 
generations (Applebaum-Shapiro et al., 2001).  Helping future generations was second only to “the 
disturbance of seeing affected relatives” as the primary motivation for genetic testing (Applebaum-
Shapiro et al., 2001).  The results also suggested that symptomatic patients are highly motivated 
to confirm their clinical diagnosis through genetic testing (Applebaum-Shapiro et al., 2001).  
About 85% responded that genetic testing results were not important for making reproductive 
decisions (Applebaum-Shapiro et al., 2001). 
1.1.3.7 Treatment 
Treatment options for chronic pancreatitis are similar for individuals with and without hereditary 
pancreatitis.  There is no cure, and available options focus on improving quality of life by reducing 
pain and malnutrition, and by removing any environmental risk factors (e.g. smoking, alcohol).  
Evaluation of pancreatic exocrine and endocrine function are important for determining the extent 
of disease and evaluate appropriate treatment options.  
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 For individuals who are known to have or be at risk for hereditary pancreatitis, early preventative 
measures can delay and potentially prevent AP attacks.  Recommended measures beginning in 
childhood include eating a low-fat diet, eating multiple small meals a day, staying hydrated, and 
taking antioxidants (Uomo, Talamini, & Rabitti, 2001). 
 
Maldigestion is treated with pancreatic enzyme replacement therapy.  This therapy is orally 
administered during meals and snacks with a dose corresponding to the fat content of the meal 
(Lindkvist, 2013).  For patients who develop diabetes, insulin therapy and antidiabetic agents, 
particularly metformin, may be beneficial (Decensi et al., 2010).  
 
Pain is a common symptom of pancreatitis and can sometimes be managed by pancreatic enzyme 
replacement therapy (Burton et al., 2011; Whitcomb et al., 2010).  If pain persists, analgesics are 
used to treat pain.  Antioxidants have also been suggested to reduce pain in hereditary pancreatitis 
(Uomo et al., 2001). 
 
Endoscopic retrograde cholangiopancreatography (ERCP) is an endoscopic procedure that can be 
used to visualize and remove obstructions or calcifications blocking the pancreatic ducts.  When 
there is a blockage, this procedure can significantly reduce pain, hospitalizations, and the 




Surgery can be considered for patients in whom therapy has not been successful in relieving 
symptoms.  For chronic pancreatitis, surgical approaches include decompression/drainage, 
pancreatic resection, and denervation of afferent nerves originating from the pancreas to reduce 
pain and/or remove inflammation.  Pancreatic resection in individuals with HP is less successful 
because it is unlikely to end inflammation and results in the removal of precious islet cells.  Total 
pancreatectomy with islet cell auto-transplantation (TPIAT) is a newer option as a last-resort to 
reduce uncontrolled pain, improve quality of life, and prevent pancreatic cancer and type 3c 
diabetes mellitus (Bellin, Freeman, et al., 2014; Bellin, Gelrud, et al., 2014; Bellin et al., 2015).  
This surgery first involves the removal of the pancreas.  The pancreatic tissue is then digested to 
isolate islet cells, which are subsequently re-implanted into another site, such as the liver or 
abdomen.  However, this procedure restricts patients to life-long pancreatic enzyme replacement 
therapy and can cause major gastrointestinal motility issues. 
1.1.4 Pancreatic Cancer Genetics 
The most common form of pancreatic cancer is pancreatic ductal adenocarcinoma, which 
comprises about 90% of cases of pancreatic cancer cases.  It is difficult to treat, and typically fatal, 
being the 4th leading cause of death from cancer in the United States (Lewis, Frost, & Venne, 
2009).  Pancreatic cancer is typically sporadic, but as many as 10% of cases can be attributed to a 
hereditary predisposition (Brand et al., 2007).  However, it is likely that there is a larger genetic 
contribution in the development of pancreatic cancer, particularly through common risk variants 
and complex gene-gene and gene-environment interactions (Solomon, Das, Brand, & Whitcomb, 
2012).   
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Major genes in which variants have been associated with inherited cancer syndromes and increased 
risk for pancreatic cancer are BRCA1, BRCA2, PALB2, ATM, CDKN2A, APC, MLH1, MSH2, 
MSH6, PMS2, TP53, PRSS2, and STK11 (Solomon et al., 2012; Syngal et al., 2015).  Familial 
pancreatic cancer is defined as pancreatic cancer in two or more first degree relatives who do not 
meet criteria for a known cancer syndrome associated with pancreatic cancer (Brand et al., 2007; 
Syngal et al., 2015).  A risk variant in the PALLD gene was found to be associated with familial 
pancreatic cancer in a large family, but has not been identified in other cases (Pogue-Geile et al., 
2006).  The majority of cases of familial pancreatic cancer do not have an identified genetic cause, 
and a responsible genetic mutation has only been identified in about 20% of cases (Syngal et al., 
2015).  Furthermore, it is unknown why some families with hereditary pancreatitis have higher 
incidences of pancreatic cancer than other families.  It has likely that other risk variants and 
complex interactions are influencing the development of pancreatic cancer in these families. 
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1.2 SPECIFIC AIMS 
1.2.1 Specific Aim 1 
To provide a description of the current HP Study Cohort in order to determine if participants with 
hereditary pancreatitis in this American cohort differ from previous studies in the US and Europe.  
1.2.2 Specific Aim 2 
To describe and analyze families with pancreatic cancer and diabetes mellitus by: 
a. Comparing risks for chronic pancreatitis, diabetes mellitus, and pancreatic cancer based 
on family history and HP status 
b. Describing large pedigrees with pancreatic cancer 
1.2.3 Specific Aim 3 
To create and implement a valuable follow-up questionnaire for this cohort to answer new 
questions on QOL, attitudes, concerns, and perceptions in participants with HP to provide 
UPMC/The University of Pittsburgh with information on how to improve care in a pancreatic 





1.3.1 Specific Aim 1 
The Hereditary Pancreatitis Cohort is a valuable resource to study the natural history of hereditary 
pancreatitis in the United States.  Comparison of this American cohort to other studies on 
populations in Europe is valuable to understanding the disease and its course.  Furthermore, the 
availability of DNA samples allows for comparisons between different genotype groups. 
 
1.3.2 Specific Aim 2 
Familial risk for pancreatic cancer and diabetes mellitus is incompletely defined in families with 
hereditary pancreatitis.  Furthermore, it is unknown why some families have greater incidence of 
pancreatic cancer and diabetes than other families.  It is expected that many risk variants and 
environmental factors play a role in the development of these outcomes.  By understanding the 
correlation between a family history of pancreatitis, diabetes mellitus, pancreatic cancer, and HP 
status, this familial risk can further be defined.  This information is valuable for personalized care 
and risk assessment by genetic counselors. 
1.3.3 Specific Aim 3 
The HP Cohort provides a valuable resource to gather attitudes, concerns, and perceptions, as well 
as follow-up medical and family information for further analysis.  Understanding emotional health 
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and quality of life for individuals with hereditary pancreatitis and their families is critical toward 
understanding the psychosocial implications of this disease.  Gathering information on concerns, 
perceptions and experiences regarding genetic testing and genetic counseling will inform the 
genetic counseling process for hereditary pancreatitis.  Concerns and perceptions regarding the 
medical, surgical, and financial aspects of this disease will help inform care for patients with HP.  
Furthermore, information about attitudes regarding a Pancreas Center of Excellence and 
experiences with total pancreatectomy with islet autotransplantation (TPIAT), a new procedure, 
will be useful to improve the care provided by the Pancreas Center of Excellence at the University 
of Pittsburgh Medical Center. 
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2.0  MATERIALS AND METHODS 
The Hereditary Pancreatitis Genetic Linkage Study (ID: PRO07090243) is currently approved by 
the University of Pittsburgh’s Institutional Review Board (Appendix A).  A modification of this 
study to include a new follow-up survey was reviewed by the University of Pittsburgh Institutional 
Review Board and approved on February 3, 2015 (Appendix B). 
2.1 DATA SOURCE 
The Hereditary Pancreatitis Study at the University of Pittsburgh began in 1994.  It has collected 
genetic, medical, and environmental data from hundreds of families with pancreatitis. Data is 
participant-reported through medical history questionnaires, and consenting participants provided 
DNA samples for genetic analysis.  Medical histories were validated from medical records when 
made available.  Participants met inclusion criteria for this study if they were age 3 months up to 
100 years and met at least one of the following criteria: 
• Diagnosis of pancreatitis at age < 60 
• Diagnosis of pancreatitis at any age and at least one other 1st or 2nd degree relative 
with a diagnosis of pancreatitis or pancreatic cancer 
• Diagnosis of pancreatic cancer and a 1st or 2nd degree relative with pancreatic cancer 
or pancreatitis 
• Diagnosis of pancreatic insufficiency or maldigestion that improves with pancreatic 
enzyme replacement 
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• Close family member of subjects who meet the above criteria 
 
This study does not have any specific exclusion criteria.  The initial goal of this study was to enroll 
patients with possible familial or hereditary pancreatitis and their families to examine genes that 
may serve as a potential resource for genetic linkage.  It was started after several large families 
with pancreatitis were identified and recruited.  This study has expanded to include over 700 
individuals from over 200 families.  From this study came the discovery of mutations in the 
cationic trypsinogen gene (PRSS1) as a major cause of hereditary pancreatitis.  Follow-up studies 
on this cohort have been performed to gather updates on personal and family history, as well as 
obtain new blood samples.  This study remains open for enrollment. 
2.2 INCLUSION CRITERIA FOR SPECIFIC AIM 1A  
For specific aim 1, participants from the Hereditary Pancreatitis Genetic Linkage study were 
included in the analysis if they reported a physician diagnosis of hereditary pancreatitis and 
provided a three-generation pedigree.  This criteria was used to make this cohort comparable to 
studies on European populations. 
2.3 ANALYTICAL METHODS FOR SPECIFIC AIM 1A  
The general cohort statistics were included as counts and percentages, or mean and range.  The 
cohort was split into two groups: (1) participants with an identified PRSS1 mutation; (2) 
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participants without an identified PRSS1 mutation, which includes individuals for which testing 
was not completed.  Comparisons between the groups were made using the Kruskal-Wallis test for 
continuous data.  The χ2 test was used for categorical data except when n ≤ 5 for a cell, in which 
case Fisher’s exact test was used. 
2.4 SPECIFIC AIM 1B – SURVIVAL ANALYSIS 
Deceased status was obtained through the free Social Security Death Index (SSDI) database search 
at Ancestry.com (Ancestry.com, 2011).  The SSDI is a database of deaths that were reported to the 
Social Security Administration (Social_Security_Administration).  Information is available from 
1962 to March of 2014.  Information is not currently available for deaths after March 2014 due to 
new legislative rules requiring that records only become available after a three year period.  First 
name, middle name, last name, date of birth (DOB), and social security number (SSN) for HP 
cases were entered into the Ancestry.com SSDI search engine.  Deceased individuals that matched 
the name and exact DOB were confirmed as the participant by SSN and/or location of birth and 
death. 
 
The survival of the cohort was estimated using the Kaplan-Meier non-parametric method with 
right censoring.  The log-rank test was used to determine the significance of survival differences 
according to gender, mutation status, smoking habits, diabetes, and pancreatic enzyme therapy.  
The end point used was date of death or March 1, 2014 according to the timeframe available from 
the SSDI.  Analyses were performed using Minitab® 16 statistical software with a critical level of 
significance of P < 0.05. 
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2.5 DATA SOURCE FOR SPECIFIC AIM 2A 
Specific aim 2A was completed using two cohorts: HP and NAPS2/CV.  See Section 2.1 for a 
description of the HP Cohort. 
 
The North American Pancreatitis Study 2 (NAPS2) ascertained 1,000 subjects with RAP or CP 
and 695 controls across twenty centers in the United States between 2000 and 2006 (Whitcomb et 
al., 2008).  Participants and their physicians completes questionnaires, and blood was obtained for 
genetic and biomarker studies.  The NAPS2-Continuation and Validation (CV) began in 2008 to 
continue the study and ascertain a validation group for genome-wide association studies (GWAS).  
2.6 ANALYTICAL METHODS FOR SPECIFIC AIM 2A 
Statistics were reported as counts and percent values.  Confidence intervals were obtained using 
standard error.  Significance was determined using a two-tailed test of two binomial proportions, 
except when n ≤ 5 for a cell, in which case Fisher’s exact test was used. 
2.7 PEDIGREE ASSESSMENT (SPECIFIC AIM 2B) 
Pedigrees were selected from the HP cohort for assessment of pancreatic cancer outcomes.  These 
pedigrees were selected because they met the following criteria: (1) Extensive number of 
participants in the study for which medical history, smoking status, and alcohol exposure is 
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available; (2) Case(s) of pancreatic cancer; and (3) an identified PRSS1 mutation.  Two pedigrees 
met this criteria and were chosen for a case series.  In each kindred, the following were assessed: 
(1) age or age at death; (2) smoking history; (3) alcohol exposure; (4) pancreatic cancer diagnosis 
and age at diagnosis; (5) PRSS1 mutation status; and (6) HP symptoms. 
2.8 QUESTIONNAIRE DESIGN (SPECIFIC AIM 3) 
Two questionnaires were created – one for cases and one for controls.  Cases are defined as 
individuals in the Hereditary Pancreatitis Genetic Linkage Study who report a physician diagnosis 
of hereditary pancreatitis.  Controls are defined as the participants without a physician diagnosis 
of hereditary pancreatitis.  The questionnaire was written to gather information from six categories: 
(1) Risk and State, (2) Emotional Health, (3) Quality of Life, (4) Concerns and Perceptions, (5), 
Genetic Testing, and (6) Genetic Counseling. 
 
The Risk and State section of the questionnaire includes questions regarding alcohol and tobacco 
exposure, current height and weight, and pain.  The alcohol and tobacco questions were designed 
to match the questions used in the North American Pancreatitis Study 2 (NAPS2) for a direct 
comparison. 
 
The Emotional Health section of the questionnaire asks questions directly related to anxiety, 
depression, and problems caused by hereditary pancreatitis.  The anxiety and depression questions 
are adapted from the Patient Reported Outcomes Measurement Information System (PROMIS®) 
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short forms 1.0 Anxiety 4a and Depression 4a.  These short forms were chosen because they are 
validated measures of anxiety and depression. 
 
The Quality of Life section of the questionnaire contains the 12-Item Short Form Survey from the 
RAND Medical Outcomes Study (SF-12® Health Survey).  This Short Form survey was designed 
to measure eight health domains: Physical Functioning, Role-Physical, Bodily Pain, Vitality, 
Social Functioning, Role-Emotional, and Mental Health.  It uses the standard 4-week recall period.  
The SF-12® was chosen over the SF-36® because of its lower respondent burden and for 
comparison purposes. 
 
Section 4, Concerns and Perceptions, can be further broken down into four categories: Medical, 
Surgical, Financial, and Pancreas Center of Excellence (COE).  The Medical section asks about 
concern regarding medical problems related to pancreatitis and perception of pancreatic cancer 
risk.  These questions were chosen to garner patient concerns about their disease and outcomes.  
The Surgical section focuses on one procedure – total pancreatectomy with islet 
autotransplantation (TPIAT).  This section asks for opinions and experiences with this newer 
surgical procedure – particularly regarding the benefits and drawbacks.  The Surgical section also 
has questions regarding TPIAT outcomes and satisfaction, which were created at the University of 
Minnesota (Sutherland et al., 2012).  The Financial section asks about the financial burdens of HP, 
and the Pancreas COE section asks about opinions on the characteristics of a pancreas COE.  This 
section is particularly relevant for the Pancreas COE at the University of Pittsburgh Medical 
Center.   
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The Genetic Testing section is designed to gather information on the benefits and drawbacks of 
genetic testing for HP, as well as participant experiences with genetic testing.  It incorporates 
motivators and concerns for genetic testing that have been previously surveyed in this HP cohort 
(Applebaum-Shapiro et al., 2001).  This section will allow for an analysis of changes in attitudes 
and concerns over the past fourteen or more years.    
 
The final section of the questionnaire asks about experiences and perceptions regarding genetic 
counseling for Hereditary Pancreatitis.  This section is expected to be useful to inform genetic 
counseling for HP.  The questionnaires for HP cases and controls can be found in Appendix D 
and Appendix E, respectively.  The results from this questionnaire will not be reported in this 
document; rather, it was developed for future studies. 
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3.0  RESULTS 
3.1 SPECIFIC AIM 1 
3.1.1 Demographics 
Out of 757 participants in the Hereditary Pancreatitis Genetic Linkage Study, 254 participants were 
found to meet the following criteria: 
(1) A physician diagnosis of hereditary pancreatitis, AND 
(2) Provision of a 3-generation family history 
All results for specific aim 1, with the exception of the survival analysis, include only these 254 
participants for the purpose of comparison to previously described cohorts in Europe.  These 
participants comprised 93 three-generation families.  Out of the 254 participants, 114 (45.6%) were 
male, and the median age at enrollment was 29 years (range 0 – 77) (Table 1).  Of these 
individuals, 78 (30.7%) were minors (≤ 17 years) at the time they were enrolled.  Participants were 
asked to identify their ethnicity/race.  238 participants (93.7%) indicated their ethnicity/race as 
Caucasian/white, making up the majority of all participants.  Other represented ethnicities included 
African American (0.4%), American Indian (0.4%), Hispanic/Latino (0.4%), and Asian (0.8%).  





Table 1 Enrollment data and demographics 
 N % of total 
Participants that meet criteria 254  
Families ( ≥ 3 generations) 93  




Female 140 55.1% 
Median age at enrollment (years) (md = 4) 29 (Range 0 – 77)  
Race/Ethnicity   
Caucasian/White 238 93.7% 
Asian 2 0.8% 
African American/Black 1 0.4% 
 
American Indian 1 0.4% 
 
Hispanic/Latino 1 0.4% 
 
Unknown (Not specified) 11 4.3% 
md = missing data 
 
3.1.2 Characteristics 
The percentage of ever smokers in this cohort was 28% (Table 2).  Chronic alcohol consumption, 
defined here as greater than 3 drinks per day for women and 4 drinks per day for men, was detected 
in 3.15% of participants.  PRSS1 mutations were detected in 74.4% of participants (R122H 83.1%, 
N29I 13.8%, R112C 1.1%, A16V 1.1%, R116C 1.1%).  SPINK1 and CFTR mutations were 
identified in 11% and 1.2% of participants, respectively.  There were no statistically significant 
differences in number of men, number of smokers, chronic alcohol consumption, or age at 
enrollment between individuals with an identified mutation and those without.   
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Table 2 Characteristics 
Characteristic 
All participants 









(n = 65) 
P 
value† 
Age at enrollment (md=4)‡ 29 years (0 - 77) 30 years (0 - 76)  28 years (5 - 77) 0.959 
Number of men 114 (45.6%) 88 26 0.359 
Number of families (≥ 3 generations) 93 families 64 families 29 families - 
Number of ever smokers 71 (28%) 55 15 0.352 
Chronic Alcohol Consumption§ 8 (3.15%) 5 3 0.426 
PRSS1 mutations (n) 189 189 - - 
R122H - 157 - - 
N29I - 26 - - 
R122C - 2 - - 
K23R - 0 - - 
A16V - 2 - - 
R116C - 2 - - 
SPINK1 mutations (md = 86) 28 (11%) 19 9 - 
CFTR mutations (md = 241) 3 (1.2%) 0 3 - 
* Includes 44 participants with incomplete PRSS1 testing 
† The Kruskall-Wallis test was used for continuous data; Chi-squared was used for categorical data when n > 5. When  
n ≤ 5 for any cell in a two-way table, Fisher’s exact test was used. Calculations were made using Minitab®. 
 
‡ Median (range) 
§ Chronic alcohol consumption is defined here as > 4 drinks per day for men and > 3 drinks per day for women  
md = missing data 
 
3.1.3 Clinical and Biochemical Features 
The median age (and range) for diagnosis of any pancreatitis and at HP diagnosis was 7 years (0 
– 73) and 13 years (1 – 66) respectively (Table 3).  There was no significant difference in age at 
first diagnosis with pancreatitis between HP participants with and without identified PRSS1 
mutations (Figure 1).  Penetrance of any pancreatitis for a known-pathogenic PRSS1 mutation was 
87% for this cohort.  When the disease definition is expanded to include endocrine insufficiency, 
exocrine insufficiency, and pancreatic calcifications, the penetrance increased to 93.3%.  84.6% 
of participants reported a diagnosis of acute pancreatitis, and 117/237 (49.4%) reported a diagnosis 
27 
of chronic pancreatitis.  Four individuals reported a diagnosis of CP in the absence of previous 
acute pancreatic attacks, none of which had an identified mutation.  69 (27.2%) of participants 
report a diagnosis of diabetes and 19 (7.5%) report having gallstones.  The median age at endocrine 
failure was 31 years.  Exocrine failure was reported by the use of pancreatic enzymes and found 
in 37% of participants.  Pancreatic cancer was identified in 3 participants and diagnosed at an 
average age of 72 years.  Cumulative rates of diagnosis with any pancreatitis, endocrine 
insufficiency, and pancreatic cancer are represented in Figure 2. 
 





PRSS1 mutations  
(n= 189) 
Patients without 
a detected PRSS1 
mutation*  
(n = 65) 
P 
value† 
Age at first diagnosis of pancreatitis‡ 
(md = 9) 7 years (0 - 73) 7 years (0.17 - 73) 11 years (0 - 55) 0.544 
Age at diagnosis with HP‡ 
(md = 175)  13 years (1 - 66) 13 (1 - 66) 20 (11-21) 0.489 
Acute pancreatitis 
(md = 1) 214 (84.6%) 159 55 0.376 
Chronic pancreatitis  
(md = 19) 117 (46.1%) 81 36 0.080 
CP without prior AP 4 (0.02%) 0 4 0.04 
Admission in intensive care unit 
(md = 186) 11 (12.8%) 7  4 0.755 
Diabetes Mellitus 69 (27.2%) 49 20 0.449 
Age at diabetes mellitus diagnosis‡ 
(md = 25) 31 years 35 years  28 years 0.427 
Use of pancreatic enzymes 94 (37%) 75 19 0.298 
Gallstones 19 (7.5%) 14 5 1.00 
* Includes 44 participants with incomplete PRSS1 testing 
† The Kruskall-Wallis test was used for continuous data; Chi-squared was used for categorical data when n > 5. When  
n ≤ 5 for any cell in a two-way table, Fisher’s exact test was used. Calculations were made using Minitab®. 
 
‡ Median (range) 
md = missing data 
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 Figure 1 Distribution by age at first diagnosis with pancreatitis 
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3.1.4 Morphological Features 
12.9% of participants reported pancreatic calcifications, and 9.4% reported the diagnosis of 
pseudocysts (Table 4).  There were no statistically significant differences in the morphologic 
features of pancreatic calcifications and pseudocysts in patients with and without an identified 
mutation. 
 
Table 4 Morphological Features 
Characteristic All patients (n=254) 
Patients with PRSS1 
mutations (n= 189) 
Patients without a 
detected PRSS1 
mutation (n = 65)* 
P 
value† 
Pancreatic calcifications 33 (12.9%) 26 7 0.537 
Pseudocysts 24 (9.4%) 16 8 0.402 
* Includes 44 participants with incomplete PRSS1 testing 
† Chi-squared test was used and calculations were made using Minitab®. 
3.1.5 Treatment 
Treatments for these participants included analgesics, endoscopic treatment, and surgical 
interventions (Table 5). 113/117 (96.6%) used analgesics at any point, with 41/89 (46.1%) 
reporting a chronic use of analgesics to treat pain.  48/170 (57.1%) reported endoscopic treatment, 
and 49/224 (21%) reported one or more pancreatic surgical treatments.  Pancreatic surgical 
treatments included Puestow (18/49; 36.7%), Whipple (6/49; 12.2%), draining procedures (3/49; 






Table 5 Treatment 
Treatment All patients (n=254) 
Patients with PRSS1 
mutations (n = 189) 
Patients without a 
detected PRSS1 
mutation (n = 65)* P value† 
Use of analgesics ever  
(md = 137) 113 (96.6%) 93 20 1.000 
Chronic use of analgesics 
(md = 165) 41 (46.1%) 35 7 0.430 
Endoscopic treatment 
(md = 84) 48 (57.1%) 35 13 0.084 
Surgical treatment 
(md = 30) 49 (21%) 39 10 0.225 
Hepaticojejunostomy/other 
biliary bypass 2 (0.01%) 1 1 0.447    
Cholecystectomy 47 (18.5%) 36 11 0.704    
* Includes 44 participants with incomplete PRSS1 testing 
† Chi-squared test was used and calculations were made using Minitab®. 
md = missing data 
 
Table 6 Surgical Interventions 
Surgical 
Intervention 
All patients (n=49) 
Patients with PRSS1 
mutations (n = 39) 
Patients without detected 
PRSS1 mutation* (n = 10) 
P 
value† N (%) 
Mean Age 
(yrs) N (%) 
Mean Age 
(yrs) N (%) 
Mean Age 
(yrs) 
Puestow 18 (36.7%) 
26.81 years 
(md=2) 13 (33.3%) 25.27 years 5 (50%) 30.20 years 0.465 
Whipple 6 (12.2%) 29.17 years 5 (7.7%) 28.8 years 1 (10%) 31 years 1.000 
Draining 
Procedure 3 (6.1%) 
20.5 years 




(total or partial) 15 (30.6%) 
31.9 years 
(md=5) 12 (30.%) 29.89 years 3 (30%) 50 years 1.000 
* Includes 44 participants with incomplete PRSS1 testing 
† Chi-squared test was used and calculations were made using Minitab®. 





3.1.6 Survival Analysis 
For survival analysis, all participants who reported a physician diagnosis of hereditary pancreatitis 
(n=271) were included.  A total of 25 (9.2%) participants were identified as deceased through the 
Social Security Death Index (SSDI).  The average age of death for deceased participants was 57 
years, with a range of 17 years to 85 years.  Median overall survival for the entire cohort was 85 
years, with a mean of 77.93years (CI 95%: 75 – 81) (Figure 3).  Mean survival for ever smokers 
and never smokers was 74.2 and 79.2 years, respectively (Figure 4).  Mean survival for males and 
females was 76.4 and 78.8 years, respectively.  Survival by mutation status was obtained for the 
following categories: PRSS1 R122H, PRSS1 N29I, and no PRSS1 mutation identified.  Mean 
survival rates for these groups were 77.6, 75.9, and 78.5 years, respectively (Figure 5).  For 
endocrine insufficiency, mean survival was 74.3 years for participants with diabetes and 81 years 
for participants without diabetes (Figure 6).  For exocrine insufficiency, mean survival was 81.9 
years for participants taking digestive enzymes and 75.3 years for participants who were not treated 
with enzyme therapy (Figure 7).  Smoking habits, gender, and mutation status were not associated 
with significant differences in survival (Table 7).  Diabetes was identified as a risk factor of 
mortality (p = 0.031).  Furthermore, lack of treatment with digestive enzymes was significantly 
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      Table 7 Log-Rank Test of Survival 
 
Category Variables P-Value 
Sex Male Female 0.476 
Smoking Status Ever-Smoker Never-smoker 0.065 
Exocrine Failure Digestive enzymes No digestive enzymes 0.022 
Endocrine Failure Diabetes No diabetes 0.031 
PRSS1 Mutation 





















    
   
 
Figure 7 HP Survival Plot by Pancreatic Enzyme Therapy Status 
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3.2 SPECIFIC AIM 2 
3.2.1 Family History Risk Analysis 
3.2.1.1 Demographics 
The NAPS2 and NAPS2 CV cohorts were found to have similar ethnic backgrounds as the 
HP cohort, with the majority of participants being Caucasian (Table 8).  Caucasian participants 
comprised 85.7% of all NAPS2/CV participants (including cases and controls) and 93.7% of the 
254 HP participants with family history information included in specific aim 1.  Both cohorts are 
from the North American population.  Fisher’s exact test was used to determine if the proportion 
of Caucasians in the HP cohort of cases is significantly different than the proportion of Caucasians 
in the NAPS2 and NAPS2 CV cohort.  A p-value of 0.008 was identified, resulting in a rejection 
of the null hypothesis and the conclusion that there is a significant difference in the proportion of 
Caucasians between the HP cases and the NAPS2/CV cohort.  The HP cases were more likely to 
be Caucasian than the NAPS2/CV participants (OR= 1.88).  However, this odds ratio corresponds 
to a Cohen’s effect size (d) value of between 0.2 and 0.5, indicating low practical effect  (H. Chen, 
Cohen, & Chen, 2010).  Therefore, these groups were deemed comparable for this analysis. 
Table 8 Demographics for NAPS2, NAPS2 CV, and HP Cohorts 
 








Total 7.7% 1.0% 87.6% 2.9% 0.8% 2567 
Controls (all) 4.9% 1.5% 89.5% 4.0% 0.2% 570 
Related Controls 5.0% 0.0% 86.6% 7.9% 0.5% 202 
Unrelated Controls 4.8% 1.9% 90.4% 2.8% 0.1% 684 
CP Cases 11.1% 0.5% 84.4% 2.3% 1.6% 1111 
RAP Cases 5.4% 1.2% 90.7% 2.5% 0.2% 570 
HP Study HP Cases 0.4% 0.7% 93% 1.1% 4.8% 271 
                Total 7.0% 1.0% 88.1% 2.7% 1.4% 2821 
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3.2.1.2 Risks for CP, DM, and PDAC 
Proportions of chronic pancreatitis (CP), diabetes mellitus (DM) and pancreatic cancer 
(PDAC) outcomes were compared between HP cases and individuals from the NAPS2/CV cohort 
with a family history of AP, CP, DM or PDAC.  No significant difference in the percentage of CP 
outcomes were found between HP cases and individuals with a family history of AP and/or CP 
from the NAPS2/CV cohorts (Table 9).  The lack of significant differences in CP outcomes 
between these cohorts makes them comparable for further analyses regarding other outcomes.   
 
A significantly higher proportion of the HP cohort had diabetes mellitus compared to the 
NAPS2/CV family history groups (Table 10).  This result confirms that diabetes mellitus is an 
outcome related to hereditary pancreatitis, and suggests that a diagnosis of HP is a higher risk 
factor for diabetes than a family history of pancreatitis, DM, or PDAC amongst these cohorts. 
 
A significant difference (p=0.003) in the proportion of pancreatic cancer outcomes was identified 
between the HP cases and participants in the NAPS2/CV cohort with a family history of diabetes 
mellitus groups (Table 11).  This data suggests that a family history of diabetes mellitus is not as 
strong a risk factor for pancreatic cancer as a diagnosis of hereditary pancreatitis amongst these 
cohorts.  Overall, this analysis supports higher risks for diabetes and pancreatic cancer in 
individuals with HP, potentially higher than the risks for these outcomes associated with a family 
history of pancreatitis, diabetes, or pancreatic cancer even in higher-risk populations. 
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Table 9 HP v. Family History:  Risks for Chronic Pancreatitis 
* HP cases and individuals with a family history of HP excluded from FHx categories from the NAPS2/CV cohorts 
† Two-tailed test of binomial proportions was used except where n ≤ 5, in which case Fisher’s exact test was 
performed. P-values represent a comparison to the HP group. 
‡ RAP cases excluded because RAP was not measured as an outcome for HP 
FHx = Family history; DM = Diabetes mellitus; PDAC = Pancreatic ductal adenocarcinoma 
 
Table 10 HP v. Family History: Risks for Diabetes Mellitus 
* HP cases and individuals with a family history of HP excluded from FHx categories from the NAPS2/CV cohorts 
† Two-tailed test of binomial proportions was used except where n ≤ 5, in which case Fisher’s exact test was 
performed. P-values represent a comparison to the HP group. 
‡ RAP cases excluded because RAP was not measured as an outcome for HP 






Cohort Category* Total (n) 
Number 





HP Cohort Diagnosis of HP 271 129 47.6% - 
NAPS2/CV 
Cohorts 
Any FHx AP‡ 221 93 42.1% 0.221 
Any FHx CP‡ 233 103 44.2% 0.446 
FHx AP (excluding FHx CP)‡ 122 63 51.6% 0.459 
 







HP Cohort Diagnosis of HP 271 69 25.5% - 
NAPS2/CV 
Cohorts 
Any FHx AP 274 33 12.0% 0.000 
Any FHx CP 269 26 9.7% 0.000 
FHx AP (excluding FHx CP) 159 23 14.5% 0.007 
FHx DM 1370 232 16.9% 0.001 
FHx PDAC 204 34 16.7% 0.021 
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Table 11 HP v. Family History: Risks for Pancreatic Cancer 
* HP cases and individuals with a family history of HP excluded from FHx categories from the NAPS2/CV cohorts 
† Two-tailed test of binomial proportions was used except where n ≤ 5, in which case Fisher’s exact test was 
performed. P-values represent a comparison to the HP group. 
‡ RAP cases excluded because RAP was not measured as an outcome for HP 
FHx = Family history; DM = Diabetes mellitus; PDAC = Pancreatic ductal adenocarcinoma 
  








HP Cohort Diagnosis of HP 271 4 1.5% - 
NAPS2/CV 
Cohorts 
Any FHx AP 274 0 0.0% 0.060 
Any FHx CP 269 0 0.0% 0.124 
FHx AP (excluding FHx CP) 159 0 0.0% 0.302 
FHx DM 1370 1 0.1% 0.003 
FHx PDAC 204 0 0.0% 0.138 
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3.2.2 Pancreatic Cancer Pedigree Case Series 
In a single family with autosomal dominant PRSS1-related hereditary pancreatitis, four cases of 
pancreatic cancer were reported over 2 generations (Figure 8).  Three of these cases were among 
first degree relatives.  Genetic testing identified the R122H PRSS1 mutation in this family.  
Smoking and alcohol status is only known for one of the cases of pancreatic cancer (III-19), and 
this individual was an ex-smoker and never-drinker.  Median age at diagnosis with pancreatic 
cancer in this family was age 53.  One case of pancreatic cancer was found in an individual with 
genetically confirmed hereditary pancreatitis (II-19), and another case was found in an obligate 
carrier (III-15).  The observation of multiple individuals affected with pancreatic cancer with and 
without hereditary pancreatitis suggest that other genetic risk factors are involved in the 
development of pancreatic cancer in this family. 
 
Pedigree 2 represents a family with one case of pancreatic cancer in an individual (II-1) who was 
a never drinker and never smoker (Figure 9).  However, other individuals in the family with HP 
were exposed to both alcohol and tobacco did not develop pancreatic cancer.  For example, 
individual IV-19 is a 3rd degree relative of II-1 with HP who reports drinking an average of 5 drinks 
per day and smoking > 1 pack per day.  Individual II-12 is a sibling of II-1 with HP who reports 
smoking > 1 pack per day.  The lack of pancreatic cancer in these individuals and other adult 
family members with major environmental risk factors suggests the presence of risk and/or 







Figure 8 Pedigree 1 
E+ = R122H PRSS1 positive        E– = PRSS1 mutation negative  
E+ = R122H PRSS1 positive        E– = PRSS1 mutation negative  
E+ 
E+           E-             E-     E+   E-    E+    E+                    E+                     E-      E+    E+ 
              2 of 4 tested  
 E- E+ 
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 Figure 9 Pedigree 2 
E+ = R122H PRSS1 positive        E– = PRSS1 mutation negative  
 E+           E+                    E+             
       E-           E-                       E+              E+     E+                       E-         E-        E+                    E+      E+   
   1 of 2 tested         1 of 3 tested 
 
     E-    E+    E-   E-  E+                        E-  E+    E+   E+  E+  E+ 
         1 of 2 tested          2 of 3 tested   
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3.3 SPECIFIC AIM 3 
Two questionnaires – cases (Appendix D) and controls (Appendix E) – were created as described 
in Section 2.7.  This questionnaire has been approved by the University of Pittsburgh Institutional 
Review Board (Appendix B).  An online version has also been created through the University of 
Pittsburgh IRB-approved Qualtrics web-based survey software.  The link to the questionnaire and 
paper versions of the survey will be mailed to current HP Study participants for a follow-up study 
and to obtain new information and attitudes, concerns, and perceptions as a future study. 
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4.0  DISCUSSION 
Hereditary pancreatitis is a rare disorder, and published literature on the natural history of HP is 
limited.  While there are many reports on clinical features in the form of case reports or small case 
series, few studies have been performed on larger scales.  Particularly, the natural history of HP 
has not been well described in the North American population.  This study represents a description 
of the cohort that has been ascertained in the United States and provides information regarding 
risks for pancreatic cancer and diabetes mellitus according to family history. 
 
The first aim of this study was to describe the HP cohort that has been obtained by the University 
of Pittsburgh.  In this HP cohort, a mutation in the PRSS1 gene was detected in 74.4% of cases, 
with a penetrance of 87% for any pancreatitis in an individual with a known pathogenic PRSS1 
mutation.  There was nearly a 4.5 year gap between the mean age of pancreatitis onset and 
diagnosis with hereditary pancreatitis, indicating a need for better recognition of this disease, 
particularly in pediatric patients.  As anticipated according to previous studies (Gorry et al., 1997; 
Whitcomb, Gorry, et al., 1996), the most common PRSS1 mutation identified was R122H, 
confirming that this is the most common mutation associated with PRSS1-related hereditary 
pancreatitis.  No statistically significant differences were found in clinical, biochemical, or 
morphological features between individuals with and without an identified mutation, with the 
exception of the occurrence of CP without prior AP favoring individuals without an identified 
mutation.  However, the potential of response bias and the small number of individuals who report 
a diagnosis of CP without prior AP (n = 4) suggest that this result has low practical significance. 
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The characteristics of this HP cohort are similar to the characteristics described in the French, 
Danish, and larger European Cohorts (Howes et al., 2004; Joergensen et al., 2010; Rebours, 
Boutron-Ruault, Schnee, et al., 2009).  Therefore, the natural history of patients with HP in the 
United States is unlikely to be substantially different from the natural history of HP in the European 
populations.  However, the percentage of individuals with HP in which PRSS1 mutations were 
identified is higher in this cohort than seen in the Danish and French studies (Howes et al., 2004; 
Joergensen et al., 2010; Rebours, Boutron-Ruault, Schnee, et al., 2009), but comparable to the 
EUROPAC study  (Howes et al., 2004).  Furthermore, rates of exocrine and endocrine 
insufficiency are higher in this population than seen in the Danish study, but similar to the French 
study (Joergensen et al., 2010; Rebours, Boutron-Ruault, Schnee, et al., 2009).  As seen in other 
studies, there is a gap of many years between symptom onset and diagnosis with HP.  
 
The mean overall survival for this HP cohort (77.93 years) is consistent with the mean survival of 
the French cohort (CI 95%: 71 – 79) (Rebours, et al. 2009), indicating that HP survival rates are 
comparable between these populations.  However, survival was likely overestimated in this case 
due to the limitations of the SSDI and the low number of participants who were greater than 60 
years of age at the time of this study.  Furthermore, participants were living at the time of 
ascertainment, which may have created a bias in the survival analysis.  In contrast to the French 
studies, diabetes and lack of pancreatic enzyme therapy were found to be risk factors of mortality 
in this cohort.  However, exocrine insufficiency was not directly measured.  Therefore, there may 
be confounding variables, such as death prior to beginning enzyme therapy, non-adherence in 
participants who do not report enzyme therapy, pancreatic resection/removal in enzyme users that 
is protective against other outcomes, and lack of therapy for individuals that would benefit.  Further 
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studies are needed to identify this correlation of diabetes and lack of enzyme therapy with lower 
rates of survival.  Furthermore, it will be valuable to compare cause of death between the 19 
deceased participants in the French cohort and the 25 deceased participants in this cohort. 
 
The family history risk analysis and case series supports the presence of complex risk variants that 
influence the development of pancreatic cancer.  Understanding and identifying these risk variants 
will help improve detection of higher-risk and lower-risk individuals, as well as help clarify the 
mechanisms behind pancreatic cancer development in families with hereditary pancreatitis. 
4.1 LIMITATIONS 
Limitations exist in the ascertainment of patient information in the HP Cohort.  Patient medical 
history is patient reported, though many reports have been verified by medical records.  
Furthermore, there is much missing data in this cohort.  Prevalence cannot be calculated from this 
study unlike studies on the French population because it is not based on a complete national series 
of patients.  As with all data, errors may exist from transferring from paper files to electronic 
systems. 
 
The Social Security Death Index is a database created from the Social Security Administration’s 
Death Master File.  It contains information on deceased individuals with social security numbers 
whose deaths were reported to the Social Security Administration.  The Social Security 
Administration cannot guarantee the accuracy of the SSDI, and missing and incorrect information 
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may exist.  Therefore, some errors may exist in the data retrieved for the survival analysis on the 
HP cohort.  
4.2 FUTURE STUDIES 
This study supports the value of this HP cohort and confirms its similarity to cohorts described in 
European populations.  As an ongoing study, it will be valuable to continue follow-up with these 
participants to further and more accurately define the natural history of HP.  Furthermore, 
identifying cause of death for deceased participants will be valuable for understanding this 
condition in the American population.   
 
Analysis of risks for chronic pancreatitis, diabetes mellitus, and pancreatic cancer based on HP 
status and family history support the influence of other genes leading to these outcomes.  Further 
studies are needed to identify genetic risk factors, modifiers, and other environmental factors that 
play a role in the development of these conditions. 
 
Finally, the survey developed for Aim 3 will be important for understanding perceptions and 
concerns of individuals with HP.  Results with inform healthcare providers and genetic counselors 
to improve care and counseling for this complex disease, particularly in a Pancreas Center of 
Excellence. 
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5.0  CONCLUSION 
This is the first study describing the natural history of hereditary pancreatitis in the United States 
on a large scale.  The similarity of this cohort to cohorts described in the European population 
makes this a good cohort for further studies on hereditary pancreatitis that may be applicable across 
populations.  This study contributes to the understanding of hereditary pancreatitis and its disease 
course, which is an important step toward improving patient care and awareness for individuals 
with this disease.  Analysis of risks for chronic pancreatitis, diabetes, and pancreatic cancer based 
on family history provided further evidence for the influence of risk genes on the development and 
inheritance of these conditions apart from HP.  This is further supported by the identification of 
HP families with a higher incidence of pancreatic cancer than expected due to HP alone.  Further 
research will define how other risk genes (or environmental risk factors) influence the outcomes 
associated with hereditary pancreatitis. 
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APPENDIX A: UNIVERSITY OF PITTSBURGH IRB RENEWAL LETTER 
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APPENDIX B: UNIVERSITY OF PITTSBURGH IRB MODIFICATION APPROVAL 
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1.1   Do you have hereditary pancreatitis? 
( 1 ) Yes  advance to question 1.2         
( 0 ) No  please complete the questionnaire for participants without hereditary pancreatitis 
( - 3 ) Unknown  please complete the questionnaire for participants without hereditary pancreatitis 
1.2   Alcohol consumption: 
NOTE:  one shot of liquor, a mixed drink, one glass of wine or one beer is considered one drink. 
Was there ever a time when you drank beer, wine, wine coolers, liquor, or mixed drinks? 
 (1) Yes            (0)  No (less than 20 drinks in your life)   Advance to question 1.3 
1.2.1 How many years did you drink alcohol in your life (this could be consecutive or non-consecutive 
periods of time)? ____ years 
Think about the period of life when you were drinking the most in your lifetime (this could be 
consecutive or non-consecutive periods of time). The next 4 questions are related to this period of your 
life:    
1.2.2 How old were you when you began drinking the most alcohol in your life? ____ 
1.2.3 On the AVERAGE about how many drinks would you have on a drinking day?  ____ 
1.2.4 How many days per month did you drink at this level?  _____ 
1.2.5 How long did you drink alcohol at the heaviest level? _____ years   or   _____ months 
1.2.6 Do you currently drink alcohol? 
 (1)Yes            (0)No   advance to question 1.3 
1.2.6.1 On the AVERAGE about how many drinks would you have on a drinking day? _____ drinks 
1.2.6.2 How many days per month did you drink at this level? _____ days per month 
1.3 Tobacco use: 
Have you ever smoked cigarettes? 
 (1) Yes                        (0) Never (less than 100 cigarettes in your life)   advance to question 1.4 
1.3.1 What age did you start smoking?  ____ years 
1.3.2 Do you currently smoke?    (1) Yes   advance to question 1.3.4        (0) No 
 1.3.2.1 What age did you quit smoking?  ____ years 
1.3.3 On the average, how many cigarettes do / did you smoke per day?  ____ 
1.4  Current Height and weight 
Height: ______  feet, _____ inches  
Usual Weight:  ______ pounds.   
Current Weight:  _____ pounds.      
Weight change over the past 6 months: ____pounds    increase in weight  decrease in weight 
Date Consent Signed: __ __ / __ __ / __ __ __ __  Confirmed (Initials: __________  ) 





   













1.5  Do you have abdominal pain from pancreatitis? 
 ( 1 ) Yes               ( 0 ) No  advance to question 2.1         ( - 3 ) Unknown  advance to question 2.1 
                    
1.5.1  What type of pain pattern do you have? (check one) 
 ( 1 )  usually pain free, but episodes of mild to moderate pain 
 ( 2 )  constant mild to moderate pain   
 ( 3 )  usually free of abdominal pain, but episodes of severe pain 
 ( 4 )  constant mild to moderate pain plus episodes of severe pain  
 ( 5 )  constant severe pain  
 
 
This section asks about the status of your emotional health related to hereditary pancreatitis, particularly feelings 
related to anxiety and depression. We recognize that hereditary pancreatitis affects both a person’s physical and 
emotional health. If you feel that you identify with any of the statements below, please let your physician know. 
You are not alone, and it may be useful for you to speak to a counselor and/or join a support group. 
Please respond to each question or statement by marking one box per row.  
2.1    Anxiety 
     2.1.1 With regard to my hereditary pancreatitis, in the past 7 days… 
       Never        Rarely    Sometimes    Often        Always 
I felt fearful…………………………………………....                                      
               (1)     (2)               (3)               (4)             (5) 
I found it hard to focus on anything other                                      
than my anxiety……………………………………..         (1)     (2)               (3)               (4)             (5) 
                
My worries overwhelmed me…………………                                      
               (1)     (2)               (3)               (4)             (5) 
I felt uneasy…………………………………………...                                      
               (1)     (2)               (3)               (4)             (5) 
 
2.2   Depression 
 2.2.1 With regard to my hereditary pancreatitis, in the past 7 days… 
       Never        Rarely    Sometimes    Often        Always 
I felt worthless……………………………………….                                      
               (1)     (2)               (3)               (4)             (5) 
I felt helpless………………………………………….                                      
               (1)     (2)               (3)               (4)             (5)              
I felt depressed………………………………………                                      
               (1)     (2)               (3)               (4)             (5) 
I felt hopeless…………………………………………                                      
               (1)     (2)               (3)               (4)             (5) 
 
2.3    Most important problems caused by hereditary pancreatitis: 
2.3.1  What is the most difficult problem for you to deal with because of hereditary pancreatitis 
in you or your family? 
 
 






   

















This survey asks for your views about your health. This information will help you keep track of how you feel and 
how you are able to do your usual activities. Answer every question by selecting the answer as indicated. If you 
are unsure about how to answer a question, please give the best answer you can. 
3.1  In general, would you say your health is:     
 Excellent (4) Very good (3)     Good (2)       Fair (1) Poor (0)   
            
 
The following questions are about activities you might do during a typical day. Does your health now 
limit you in these activities? If so, how much? 
        Yes    Yes  No not 
limited   limited    limited  
a lot (2)  a little (1) at all (0)  
3.2   Moderate activities, such as moving   
 a table, pushing a vacuum cleaner,       
bowling, or playing golf 
 
3.3 Climbing several flights of stairs        
      
During the past 4 weeks, have you had any of the following problems with your work or other regular 
daily activities as a result of your physical health?  
 Yes No 
 (1) (2)      
3.4 Accomplished less than you would like           
  
3.5   Were limited in the kind of work                                   
 or other activities 
      
During the past 4 weeks, have you had any of the following problems with your work or other regular 
daily activities as a result of any emotional problems (such as feeling depressed or anxious)? 
 Yes No 
 (1) (0)      
3.6 Accomplished less than you would like           
  
3.7 Did work or other activities less                        
 carefully than usual  
               
During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the 
home and housework)? 
3.8 Not at all (0)   A little bit (1)   Moderately (2)  Quite a bit (3) Extremely (4)    
                                                                        
               
 








   
                   













These questions are about how you feel and how things have been with you during the past 4 weeks. For 
each question, please give the one answer that comes closest to the way you have been feeling. How 
much of the time during the past 4 weeks...        
   All of   Most of          Some of A little of       None of 
 the time the time the time  the time the time  
 (4) (3)     (2) (1) (0) 
3.9 Have you felt calm and peaceful?             
3.10 Did you have a lot of energy?           
3.11 Have you felt downhearted and blue?           
               
3.12 During the past 4 weeks, how much of the time has your physical health or emotional problems interfered 
with your social activities (like visiting friends, relatives, etc.) 
   All of   Most of Some of A little of         None of   
 the time  the time  the time   the time     the time  
 (4) (3) (2) (1) (0) 
            
 
This sections asks about your concerns and perceptions related to hereditary pancreatitis. It is composed of four 
sections that ask about your perspectives on the medical, surgical, and financial aspects of hereditary pancreatitis, 
as well as your views on the characteristics of a Pancreas Center of Excellence (described below). Your concerns 
and perceptions are important to us to understand so that we can improve care for individuals with hereditary 
pancreatitis. The sub-categories in this section are as follows: 
  A. Medical 
  B. Surgical 
  C. Financial 
  D. Pancreas Center of Excellence 
Please respond to each question or statement by marking one box per row. 
 
A. Medical 
4.1.1 Prior to today, how have you felt about the following medical problems related to pancreatitis? 
 










Malnutrition  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Continuous Pain  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Narcotic Addiction  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Getting Adequate 
Treatment 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Diabetes  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Pancreatic Cancer  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
 




4.1.3 How would you describe your chances to develop pancreatic cancer? 
 
             Extremely unlikely      Unlikely   Neutral    Likely         Extremely Likely 
    ( 1 )          ( 2 )   ( 3 )   ( 4 )   ( 5 )  








   














4.1.4 Have you been counseled on your risks to develop cancer? 
   ( 1 )  Y e s      ( 2 ) N o        ( 3 ) U n k n o w n  
B. Surgical 
 A total pancreatectomy is a newer procedure that involves the removal of the entire pancreas. The 
decision to have a total pancreatectomy is dependent on a number of risks and benefits. We are looking 
to further understand the benefits, drawbacks, and outcomes of a total pancreatectomy, and this section 
asks for your opinions and experiences with this surgical procedure.  
4.2.1 Have you had or considered a total pancreatectomy with islet autotransplantation (TPIAT)?  
    Y e s ( 1 )    N o ( 0 )   go to question 4.3 
            
 4.2.1.1 How important to you are the following benefits and drawbacks of a total pancreatectomy? 
 













 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Reduction of 
abdominal pain 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Reduced risk for 
pancreatic cancer 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Preventing 
diabetes 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Acquiring diabetes  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Risks of undergoing 
surgery 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Financial costs  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
4.2.2 Have you had a total pancreatectomy with islet autotransplantation (TPIAT)?  
    Y e s ( 1 )    N o ( 0 )   advance to question 4.3      
                             
4.2.2.1 Please describe your reason for getting a total pancreatectomy and your experiences as 
compared to your expectations. (short answer) 
 
 
 4.2.2.2 The following questions ask about your experiences with a total pancreatectomy. Please 
check one box per question. 
a. Compared to the time before your pancreatectomy and islet auto-transplantation, how would 
you rate your health in general now?  
1    Much better now  
2    Somewhat better now  
3    About the same  
4    Somewhat worse now  







   














b. Compared to the time before your pancreatectomy and islet auto-transplantation, how would 
you rate your level of pain now?  
1    Much better now  
2    Somewhat better now  
3    About the same  
4    Somewhat worse now  
5    Much worse now  
 
c. Would you recommend pancreatectomy and islet auto-transplantation to your family or 
friends if they needed care for a similar problem?  
1    Definitely not  
2    Probably not  
3    Not sure  
4    Probably yes  
5    Definitely yes  
 
d. How would rate the overall results of your pancreatectomy and islet auto-transplantation?  
1    Excellent  
2    Very good  
3    Good  
4    Fair  
5    Poor 
 
C. Financial 
4.3   How important to you are the following financial burdens of having hereditary pancreatitis? 
 
 










Cost of medical 
treatment 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Costs of surgery  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
School or work 
limitations 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Requiring 
caretaker(s) 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
      
 
D. Pancreas Center of Excellence 
A Center of Excellence is an academic center that provides leadership, research, and the most up-to-date services 
in a given field. At the University of Pittsburgh, we are developing a Pancreas Center of Excellence that strives to 
provide leadership, quality patient education, and advanced care and services for pancreatic diseases, including 
hereditary pancreatitis. A Pancreas Center of Excellence also aims to research and develop new therapies and 
treatments. In order to provide the best possible care to our patients in this center, we are asking your opinions 









   














4.4 How important to you are the following characteristics of an academic multidisciplinary pancreatic 
center of excellence? 
 










Expert providers  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Nearby location  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Low financial costs  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Advanced treatment 
options 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  




 The decision to pursue genetic testing for hereditary pancreatitis is a personal decision. There are a number 
of factors that motivate individuals to pursue genetic testing, as well as reasons that individuals choose not to get 
genetic testing. If you have not had genetic testing for hereditary pancreatitis and you are interested, we suggest 
that you speak with your physician and/or genetic counselor. 
 Please respond to each question or statement by marking one box per row. 










To help one’s future 
generations 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
To learn more about 
yourself 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
To help others through 
research 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Improvement of personal 
medical care 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Presymptomatic testing 
to reduce uncertainty or 
anxiety  
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Pressure from relatives  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
The disturbing emotions 
prompted by witnessing 
a relative afflicted with 
hereditary pancreatitis 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
 








   













5.2    How important to you are the following possible reasons to NOT get genetic testing for 
hereditary pancreatitis?  
 












 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Employment 
discrimination 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Being treated 
differently by 
family and friends 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Not wanting to 
know 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Testing is not useful  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Financial costs  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
    5.3 Have you had genetic testing for your hereditary pancreatitis and were told the results of the 
genetic test(s)?  
   Y e s ( 1 )  c o n t i n u e    N o ( 0 )   advance to question 5.3.5 
   
5.3.1 Was your genetic testing before or after you began to have physical symptoms of 
pancreatitis?  
   Before (1) 
   After 
   Not applicable 
5.3.2 Which of the following reasons to GET genetic testing was most important in your decision 
to test? 
(Drop Down) 
  To help one’s future generations 
  To learn more about yourself 
  To help others through research 
  Improvement of personal medical care 
  Presymptomatic testing to reduce uncertainty or anxiety  
  Pressure from relatives 
  The disturbing emotions prompted by witnessing a relative afflicted with HP 
  None of the above 
 
 5.3.3 Who recommended genetic testing to you? (please check all that apply)  
      Yourself 
      A family member 
      Your physician 









   













5.3.4 Please describe the questions you had and the information, if any, that you were lacking 





5.3.5 What do you believe the chances are for a parent to pass on hereditary pancreatitis to his or 
her children? 
      100% 
      50% (1 in 2) 
      25% (1 in 4) 
      0% (no chance) 




Genetic counselors are professionals trained to discuss testing options to determine if a person has a genetic disorder, as well as 
the chances that a genetic disorder can be passed on to a person’s children. Genetic counselors also address the physical, 
mental, social and emotional impacts of a genetic condition. This section asks you about your experiences and perceptions on 
genetic counseling for hereditary pancreatitis. 
6.1 Have you spoken to a genetic counselor regarding hereditary pancreatitis?  
   Y e s ( 1 )  c o n t i n u e    N o ( 0 )   advance to question 6.2        
               










6.2 Please describe the information, if any, that you think should be provided by a genetic counselor 




6.3 Which of the following provided the most useful information to you about hereditary pancreatitis? 
      Yourself (researched disease on own) 
      A family member 
      A physician 
      A genetic counselor 
      Not applicable 
      Other  If you selected other, please specify: 
 
 






















             
  














  - 
 
1)  
1.1   Do you have hereditary pancreatitis? 
( 1 ) Yes   please complete the questionnaire for participants with hereditary pancreatitis             
( 0 ) No  advance to question 1.2         ( - 3 ) Unknown  advance to question 1. 2 
1.2   Alcohol consumption: 
 NOTE:  one shot of liquor, a mixed drink, one glass of wine or one beer is considered one drink. 
 Was there ever a time when you drank beer, wine, wine coolers, liquor, or mixed drinks? 
  (1) Yes            (0)  No (less than 20 drinks in your life)   Advance to question 1.3 
1.2.1 How many years did you drink alcohol in your life (this could be consecutive or non-consecutive 
periods of time)? ____ years 
Think about the period of life when you were drinking the most in your lifetime (this could be 
consecutive or non-consecutive periods of time). The next 4 questions are related to this period of your 
life:    
  1.2.2 How old were you when you began drinking the most alcohol in your life? ____ 
  1.2.3 On the AVERAGE about how many drinks would you have on a drinking day?  ____ 
  1.2.4 How many days per month did you drink at this level?  _____ 
  1.2.5 How long did you drink alcohol at the heaviest level? _____ years   or   _____ months 
 1.2.6 Do you currently drink alcohol? 
  (1)Yes            (0)No   advance to question 1.3 
 1.2.6.1 On the AVERAGE about how many drinks would you have on a drinking day? _____ drinks 
 1.2.6.2 How many days per month did you drink at this level? _____ days per month 
1.3 Tobacco use: 
 Have you ever smoked cigarettes? 
  (1) Yes                        (0) Never (less than 100 cigarettes in your life)   advance to question 1.4 
 1.3.1 What age did you start smoking?  ____ years 
 1.3.2 Do you currently smoke?    (1) Yes   advance to question 1.3.3       (0) No 
              1.3.2.3 What age did you quit smoking?  ____ years 
 1.3.3 On the average, how many cigarettes do / did you smoke per day?  ____ 
 1.4  Current Height and weight 
Height: ______  feet, _____ inches  
Usual Weight:  ______ pounds.    
Current Weight:  _____ pounds.       
Weight change over the past 6 months: ____pounds    increase in weight  decrease in weight 
Date Consent Signed: __ __ / __ __ / __ __ __ __   Confirmed (Initials: __________  ) 
 








   













1.5  Have you been diagnosed with pancreatitis? 
 ( 1 ) Yes               ( 0 ) No  advance to question 2.1         ( - 3 ) Unknown  advance to question 2.1 
                    
 1.5.1 Do you have abdominal pain from pancreatitis? 
 ( 1 ) Yes               ( 0 ) No  advance to question 2.1         ( - 3 ) Unknown  advance to question 2.1 
                    
 1.5.1.1  What type of pain pattern do you have? (check one) 
 ( 1 )  usually pain free, but episodes of mild to moderate pain 
 ( 2 )  constant mild to moderate pain   
 ( 3 )  usually free of abdominal pain, but episodes of severe pain 
 ( 4 )  constant mild to moderate pain plus episodes of severe pain  
 ( 5 )  constant severe pain  
 
This section asks about the status of your emotional health, particularly feelings related to anxiety and depression. 
If you feel that you identify with any of the statements below, please let your physician know. You are not alone, 
and it may be useful for you to speak to a counselor and/or join a support group. 
Please respond to each question or statement by marking one box per row.  
2.1    Anxiety 
     2.1.1 With regard to my health, in the past 7 days… 
       Never        Rarely    Sometimes    Often        Always 
I felt fearful…………………………………………....                                      
               (1)     (2)               (3)               (4)             (5) 
I found it hard to focus on anything other                                      
than my anxiety……………………………………..         (1)     (2)               (3)               (4)             (5) 
                
My worries overwhelmed me…………………                                      
               (1)     (2)               (3)               (4)             (5) 
I felt uneasy…………………………………………...                                      
               (1)     (2)               (3)               (4)             (5) 
2.2   Depression 
 2.2.1 With regard to my health, in the past 7 days… 
       Never        Rarely    Sometimes    Often        Always 
I felt worthless……………………………………….                                      
               (1)     (2)               (3)               (4)             (5) 
I felt helpless………………………………………….                                      
               (1)     (2)               (3)               (4)             (5)              
I felt depressed………………………………………                                      
               (1)     (2)               (3)               (4)             (5) 
I felt hopeless…………………………………………                                      
               (1)     (2)               (3)               (4)             (5) 








   













 2.3    Most important problems caused by hereditary pancreatitis: 
2.3.1  What is the most difficult problem for you to deal with because of hereditary pancreatitis 
in you or your family? 
 
2.3.2 Why is the problem noted in the previous question the most important problem? 
 
 
This survey asks for your views about your health. This information will help you keep track of how you feel and 
how you are able to do your usual activities. Answer every question by selecting the answer as indicated. If you 
are unsure about how to answer a question, please give the best answer you can. 
3.1  In general, would you say your health is:     
 Excellent (4) Very good (3)     Good (2)       Fair (1) Poor (0)   
           
 
The following questions are about activities you might do during a typical day. Does your health now 
limit you in these activities? If so, how much? 
        Yes    Yes  No not 
limited   limited    limited  
a lot (2)  a little (1) at all (0)  
3.2   Moderate activities, such as moving   
 a table, pushing a vacuum cleaner,       
bowling, or playing golf 
 
3.3 Climbing several flights of stairs        
      
During the past 4 weeks, have you had any of the following problems with your work or other regular 
daily activities as a result of your physical health?  
 Yes No 
 (1) (2)      
3.4 Accomplished less than you would like            
   
3.5 Were limited in the kind of work                      
















   













      
During the past 4 weeks, how much of the time have you had any of the following problems with your 
work or other regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious)? 
 Yes No 
 (1) (0)      
3.6 Accomplished less than you would like             
3.7 Did work or other activities less                        
 carefully than usual  
               
During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the 
home and housework)? 
3.8 Not at all (0)   A little bit (1)   Moderately (2)  Quite a bit (3) Extremely (4)    
             
               
These questions are about how you feel and how things have been with you during the past 4 weeks. For 
each question, please give the one answer that comes closest to the way you have been feeling. How 
much of the time during the past 4 weeks...  
   All of   Most of          Some of A little of       None of 
 the time the time the time  the time the time  
 (4) (3)     (2) (1) (0) 
3.9 Have you felt calm and peaceful?             
3.10 Did you have a lot of energy?           
3.11 Have you felt downhearted and blue?           
_______________________________________________________________________________________ _____ 
3.12 During the past 4 weeks, how much of the time has your physical health or emotional problems interfered 
with your social activities (like visiting friends, relatives, etc.) 
   All of   Most of Some of A little of         None of   
 the time  the time  the time   the time     the time  
 (4) (3) (2) (1) (0) 
            
 
This sections asks about your concerns and perceptions related to hereditary pancreatitis. It is composed of four 
sections that ask about your perspectives on the medical, surgical, and financial aspects of hereditary pancreatitis, 
as well as your views on the characteristics of a Pancreas Center of Excellence (described below). Your concerns 
and perceptions are important to us to understand so that we can improve care for individuals with hereditary 
pancreatitis. The sub-categories in this section are as follows: 
  A. Medical 
  B. Surgical 
  C. Financial 
  D. Pancreas Center of Excellence 
Please respond to each question or statement by marking one box per row. 
 








   













A. Medical  
Please complete the following section only if you have been diagnosed with pancreatitis. If you have 
not been diagnosed with pancreatitis, please skip to section 4C (Financial). 
4.1.1 Prior to today, how have you felt about the following medical problems related to pancreatitis? 
 










Malnutrition  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Continuous Pain  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Narcotic Addiction  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Getting Adequate 
Treatment 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Diabetes  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Pancreatic Cancer  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
4.1.2 Please describe any concerns for pancreatitis that are not listed above. 
 
 
4.1.3 How would you describe your chances to develop pancreatic cancer? 
             Extremely unlikely      Unlikely   Neutral    Likely         Extremely Likely 
    ( 1 )          ( 2 )   ( 3 )   ( 4 )   ( 5 )  
 4.1.4 Have you been counseled on your risks to develop cancer? 
   ( 1 )  Y e s      ( 2 ) N o        ( 3 ) U n k n o w n  
B. Surgical  
Please complete the following section if you have been diagnosed with pancreatitis. If you have not 
been diagnosed with pancreatitis, please skip to section 4C (Financial). 
 
 A total pancreatectomy is a newer procedure that involves the removal of the entire pancreas. The 
decision to have a total pancreatectomy is dependent on a number of risks and benefits. We are looking 
to further understand the benefits, drawbacks, and outcomes of a total pancreatectomy, and this section 
asks for your opinions and experiences with this surgical procedure.  
4.2.1 Have you had or considered a total pancreatectomy with islet autotransplantation (TPIAT)?  
    Y e s ( 1 )    N o ( 0 )   go to question 4.3 










   













 4.2.1.1 How important to you are the following benefits and drawbacks of a total pancreatectomy? 
 













 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Reduction of 
abdominal pain 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Reduced risk for 
pancreatic cancer 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Preventing 
diabetes 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Acquiring diabetes  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Risks of undergoing 
surgery 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Financial costs  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
4.2.2 Have you had a total pancreatectomy with islet autotransplantation?  
    Y e s ( 1 )    N o ( 0 )   advance to question 4.3 
           
4.2.2.1 Please describe your reason for getting a total pancreatectomy and your experiences as 
compared to your expectations. (short answer) 
 
 
 4.2.2.2 The following questions ask about your experiences with a total pancreatectomy. Please 
check one box per question. 
a. Compared to the time before your pancreatectomy and islet auto-transplantation, how would 
you rate your health in general now?  
1    Much better now  
2    Somewhat better now  
3    About the same  
4    Somewhat worse now  
5    Much worse now  
 
b. Compared to the time before your pancreatectomy and islet auto-transplantation, how would 
you rate your level of pain now?  
1    Much better now  
2    Somewhat better now  
3    About the same  
4    Somewhat worse now  






   













c. Would you recommend pancreatectomy and islet auto-transplantation to your family or friends 
if they needed care for a similar problem?  
1    Definitely not  
2    Probably not  
3    Not sure  
4    Probably yes  
5    Definitely yes  
 
d. How would rate the overall results of your pancreatectomy and islet auto-transplantation?  
1    Excellent  
2    Very good  
3    Good  
4    Fair  
5    Poor 
C. Financial 
4.3   How important to you and your family are the following financial burdens of hereditary 
pancreatitis? 
 










Cost of medical 
treatment 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Costs of surgery  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
School or work 
limitations 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Requiring 
caretaker(s) 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
D. Pancreas Center of Excellence 
A Center of Excellence is an academic center that provides leadership, research, and the most up-to-date services 
in a given field. At the University of Pittsburgh, we are developing a Pancreas Center of Excellence that strives to 
provide leadership, quality patient education, and advanced care and services for pancreatic diseases, including 
hereditary pancreatitis. A Pancreas Center of Excellence also aims to research and develop new therapies and 
treatments. In order to provide the best possible care to our patients in this center, we are asking your opinions 















   













4.4 How important to you are the following characteristics of an academic multidisciplinary pancreatic 
center of excellence? 
 










Expert providers  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Nearby location  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Low financial costs  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Advanced treatment 
options 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
New research studies  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
 
 
 The decision to pursue genetic testing for hereditary pancreatitis is a personal decision. There are a number 
of factors that motivate individuals to pursue genetic testing, as well as reasons that individuals choose not to get 
genetic testing. If you have not had genetic testing for hereditary pancreatitis and you are interested, we suggest 
that you speak with your physician and/or genetic counselor. 
 Please respond to each question or statement by marking one box per row. 










To help one’s future 
generations 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
To learn more about 
yourself 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
To help others through 
research 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Improvement of personal 
medical care 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Presymptomatic testing 
to reduce uncertainty or 
anxiety 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Pressure from relatives  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
The disturbing emotions 
prompted by witnessing 
a relative afflicted with 
hereditary pancreatitis 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
 








   













5.2    How important to you are the following possible reasons to NOT get genetic testing for 
hereditary pancreatitis?  
 












 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Employment 
discrimination 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Being treated 
differently by 
family and friends 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Not wanting to 
know 
 ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Testing is not useful  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
Financial costs  ( 1 )   ( 2 )   ( 3 )   ( 4 )   ( 5 )  
    5.3 Have you had genetic testing for your hereditary pancreatitis and were told the results of the 
genetic test(s)?  
   Y e s ( 1 )  c o n t i n u e    N o ( 0 )   advance to question 5.3.5 
   
5.3.1 Was your genetic testing before or after you began to have physical symptoms of 
pancreatitis?  
   Before (1) 
   After 
    Not applicable 
5.3.2 Which of the following reasons to GET genetic testing was most important in your decision 
to test? 
(Drop Down) 
  To help one’s future generations 
  To learn more about yourself 
  To help others through research 
  Improvement of personal medical care 
  Presymptomatic testing to reduce uncertainty or anxiety  
  Pressure from relatives 
  The disturbing emotions prompted by witnessing a relative afflicted with HP 
  None of the above 
 5.3.3 Who recommended genetic testing to you? (please check all that apply)  
      Yourself 
      A family member 
      Your physician 




   













5.3.4 Please describe the questions you had and the information, if any, that you were lacking 
after you were given your genetic test results. 
 
 
5.3.5 What do you believe the chances are for a parent to pass on hereditary pancreatitis to his or 
her children? 
      100% 
      50% (1 in 2) 
      25% (1 in 4) 
      0% (no chance) 
      Unknown 
 
 
Genetic counselors are professionals trained to discuss testing options to determine if a person has a genetic disorder, as well as 
the chances that a genetic disorder can be passed on to a person’s children. Genetic counselors also address the physical, 
mental, social and emotional impacts of a genetic condition. This section asks you about your experiences and perceptions on 
genetic counseling for hereditary pancreatitis. 
6.1 Have you spoken to a genetic counselor regarding hereditary pancreatitis?  
   Y e s ( 1 )  c o n t i n u e    N o ( 0 )   advance to question 6.2        
   
             








6.2 Please describe the information, if any, that you think should be provided by a genetic counselor 
regarding hereditary pancreatitis. 
 
 
6.3 Which of the following provided the most useful information to you about hereditary pancreatitis? 
      Yourself (researched disease on own) 
      A family member 
      A physician 
      A genetic counselor 
      Not applicable 
      Other  If you selected other, please specify: 
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